We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

ERBA MANNHEIM

Erba Mannheim is an IVD solutions provider focused on improving health outcomes in developing nations. Originally fou... read more Featured Products: More products

Download Mobile App





ERBA Group Launches New Hematology Analyzers at MEDLAB 2019

By Theresa Herman, Regional Director
Posted on 27 Mar 2019
ERBA Diagnostics Mannheim GmbH (Mannheim, Germany) launched its latest hematology analyzers at MedLab Middle East, an international platform for laboratory management and medicine that was held between February 4-7, 2019, at the Dubai International Convention and Exhibition Centre, Dubai, UAE.

ERBA is a global in-vitro diagnostic company that provides a comprehensive portfolio in different specialties including clinical chemistry, immunology, hematology, hemostasis, critical care, electrophoresis, urine analysis, diabetes monitoring, autoimmune & infectious disease monitoring and microbiology. More...
Its latest hematology analyzers, H 360 and H 560, launched at MedLab 2019 are designed for improving lab efficiency and are targeted at small to medium laboratories.

The newly launched, H 360 3-part differential analyzer can run up to 60 samples/hour and requires only 9 microliters of blood. The H 560 5-part differential analyzer also runs 60 samples/hour and requires only 15 microliters, which is highly beneficial in pediatric cases. In both systems, interpretation of results is aided using an advanced 3D scattergram. At MedLab 2019, ERBA also displayed the latest version of its fully automated urine chemistry and sediment analyzer, Laura XL which uses digital microscopy and AI technology to auto-recognize 16 urine sediment elements. Moreover, the photometric urine strip reader aids in the precise determination of 10 analytes using ERBA’s standardized test strips DekaPHAN.

ERBA’s team of experts provided a first-hand experience to the delegates on the new systems with more than 10 demonstrations being conducted each day. During the exhibition, customer interactions were complemented by a series of informational presentations conducted by industry experts and ERBA team members. Insightful discussions on the benefits of fast reporting for better treatment outcomes, validation methods for clinical chemistry systems, and the advantages of AMH ELISA testing were held, in addition to presentations on Laura XL, H 360 and 560 and the ELISA test range made by its US subsidiary, Calbiotech Inc.

“We are glad to be associated with MedLab as it offers an opportunity to interact with customers from across the world,” said Nikhil Vazirani, CEO, ERBA Group. “ERBA operates in a dynamic global economy and MedLab gives us a great opportunity to help understand changing customer needs and how we should adapt our technologies to offer seamless services. We are committed to focusing our products and solutions on the emerging markets and impacting a billion lives globally.”



New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Uric Acid Meter
PA-16
New
HAV Rapid Test
OnSite HAV IgG/IgM Rapid Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: The new technology combines a rapid hemoglobin test with a smartphone app (Photo courtesy of 123RF)

Smartphone-Based Rapid Hemoglobin Test Accurately Detects Colorectal Cancer

Despite the availability of colorectal cancer screening programs, participation remains low, especially for fecal immunochemical tests (FIT), a non-invasive method to detect hidden blood in the stool.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.